1. [CASE 1 — QUESTION 1] M.S. is a 64-year-old man with hypertension, HFrEF (EF 28%), permanent atrial fibrillation, and type 2 diabetes. His current medications are sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, furosemide 40 mg daily, and empagliflozin 10 mg daily. BP is 158/90 mmHg. Heart rate is 88 bpm. He is euvolemic. His cardiologist wants to initiate a beta-blocker for guideline-directed HFrEF therapy and AF rate control simultaneously. Which of the following correctly identifies the most appropriate beta-blocker for this patient, and why not all beta-blockers with HFrEF evidence are equally appropriate for combined rate control in AF?

• A) Bisoprolol is preferred for this patient because it provides stronger AF rate control than carvedilol through its higher beta-1 selectivity at the AV node, and its once-daily dosing improves adherence in a complex regimen
• B) Metoprolol succinate is preferred because it has both MERIT-HF mortality evidence in HFrEF and stronger rate control evidence in AF than carvedilol or bisoprolol, based on the AF-CHF trial data
• C) Carvedilol is preferred because its alpha-1 blockade provides additional rate control through peripheral vasodilation that reduces the sympathetic drive sustaining AF
• D) All three evidence-based beta-blockers (carvedilol, metoprolol succinate, bisoprolol) are appropriate for HFrEF mortality reduction; however, for combined HFrEF therapy and AF rate control, carvedilol and bisoprolol both provide effective AV nodal rate control through beta-1 blockade; metoprolol succinate is also effective; the choice between them should be individualized based on tolerability, dosing convenience, and whether the combined alpha-1 blockade of carvedilol provides additional benefit (vasodilation for BP control, as in this patient); carvedilol 3.125 mg twice daily is a reasonable starting point given the dual HFrEF and BP indication
• E) Beta-blockers are contraindicated in atrial fibrillation with HFrEF because the negative chronotropy required for rate control will further depress the already-compromised left ventricular function

2. [CASE 1 — QUESTION 2] Carvedilol is started at 3.125 mg twice daily and titrated to 12.5 mg twice daily over 8 weeks. M.S.'s BP is now 138/82 mmHg and heart rate is 68 bpm. His EF on repeat echo has improved to 36%. However, his HbA1c has risen from 7.4% to 8.1% over the 4-month period. His diabetologist attributes part of this worsening to carvedilol and considers switching to a more cardioselective agent. Which of the following most accurately describes the metabolic trade-off between carvedilol and cardioselective beta-blockers in type 2 diabetes, and whether switching is appropriate at this stage?

• A) The metabolic trade-off is real but must be weighed carefully against the clinical situation: carvedilol's non-selective beta-blockade (including beta-2) impairs skeletal muscle glucose uptake and glycogenolysis more than cardioselective agents; however, switching from carvedilol to bisoprolol or metoprolol succinate mid-titration in a patient who has demonstrated EF improvement and hemodynamic stability risks destabilizing a carefully established GDMT regimen; the more appropriate approach is to optimize diabetes management (intensify the empagliflozin dose or add another agent) while maintaining carvedilol; switching beta-blockers mid-course should be reserved for intolerable adverse effects, not metabolic optimization alone
• B) Carvedilol's metabolic effects on glycemic control are entirely mediated through beta-2 receptor blockade in skeletal muscle; switching to bisoprolol will completely resolve the HbA1c elevation without any loss of HFrEF benefit
• C) The HbA1c rise is unrelated to carvedilol; cardioselective and non-selective beta-blockers have identical metabolic profiles in type 2 diabetes; the diabetologist's attribution is pharmacologically incorrect
• D) Carvedilol must be switched to metoprolol succinate immediately — continuing carvedilol in a diabetic patient with rising HbA1c constitutes a contraindication; metoprolol's MERIT-HF evidence provides equivalent HFrEF benefit with better metabolic tolerability
• E) Carvedilol should be switched to bisoprolol because bisoprolol has a proven metabolic advantage over carvedilol in type 2 diabetes based on the GEMINI trial, which demonstrated bisoprolol improved insulin sensitivity while carvedilol worsened it

3. [CASE 1 — QUESTION 3] M.S. is now on carvedilol 25 mg twice daily (target dose), sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, furosemide 40 mg daily, and empagliflozin 10 mg daily. His EF has improved to 42%, BP is 128/78 mmHg, and heart rate is 62 bpm at his 12-month review. His diabetes management has been optimized and HbA1c is 7.6%. He is now functionally NYHA Class II. His cardiologist is asked by a colleague whether, given the EF recovery to 42% (now above the HFrEF threshold of 40%), any of the HFrEF medications can be discontinued to simplify the regimen. Which of the following most accurately reflects the evidence-based approach to this question?

• A) All HFrEF medications should be continued — EF recovery on GDMT does not indicate disease remission; trials of beta-blocker and RAAS inhibitor withdrawal in patients with recovered EF consistently show LV dysfunction recurs in the majority of patients when therapy is withdrawn; the improved EF reflects successful pharmacological suppression of the pathological remodeling process, not structural cure
• B) Carvedilol can be discontinued since EF has recovered above 40% — the HFrEF indication for carvedilol is defined by EF below 40%, and once EF normalizes, guideline-directed beta-blocker therapy is no longer required
• C) All HFrEF medications should be continued — EF recovery on GDMT does not indicate disease remission; trials of beta-blocker and RAAS inhibitor withdrawal in patients with recovered EF consistently show LV dysfunction recurs in the majority of patients when therapy is withdrawn; the improved EF reflects successful pharmacological suppression of the pathological remodeling process, not structural cure; additionally, M.S. still has AF and diabetes, which provide independent indications for carvedilol (rate control) and empagliflozin (cardiovascular risk reduction), reinforcing continued therapy across all agents
• D) Spironolactone can be discontinued since the patient is NYHA Class II — RALES demonstrated benefit only in NYHA Class III–IV; Class II patients do not benefit from MRA therapy
• E) Furosemide can be discontinued since the patient is euvolemic and NYHA Class II — loop diuretics are symptom-management agents only and carry no mortality benefit; discontinuation in an asymptomatic patient is guideline-recommended

4. [CASE 1 — QUESTION 4] M.S. develops worsening bilateral lower extremity edema at 18 months. BNP has risen from 280 to 420 pg/mL. His weight has increased by 3 kg over 3 weeks. His cardiologist increases furosemide from 40 mg to 80 mg daily. At 2 weeks his weight returns to baseline, edema resolves, and BNP falls to 310 pg/mL. His BP is now 118/72 mmHg and heart rate is 58 bpm. His cardiologist considers whether the carvedilol dose should be reduced given the lower BP and heart rate. Which of the following most accurately guides this decision?

• A) Reduce carvedilol to 12.5 mg twice daily — a BP of 118/72 mmHg and heart rate of 58 bpm indicate excessive beta-blockade; dose reduction is mandatory to avoid hemodynamic compromise
• B) Maintain carvedilol at 25 mg twice daily — the BP of 118/72 mmHg and heart rate of 58 bpm are within the acceptable range for a patient with HFrEF and AF on maximally tolerated GDMT; the mortality benefit of carvedilol in HFrEF is dose-dependent and achieved at target doses; reducing the dose sacrifices proven outcome benefit; if the patient is asymptomatic (no dizziness, no presyncope, no fatigue limiting function), maintaining target dose is appropriate; the BNP reduction and weight normalization confirm the decompensation was furosemide-responsive fluid overload rather than worsening carvedilol intolerance
• C) Discontinue carvedilol and switch to ivabradine — ivabradine provides equivalent HFrEF mortality benefit to carvedilol without affecting blood pressure, making it preferable when BP is at the lower range of normal
• D) Reduce furosemide back to 40 mg daily and reduce carvedilol to 12.5 mg simultaneously — the combination of maximized furosemide and target-dose carvedilol creates excessive hemodynamic load reduction
• E) Add midodrine 5 mg three times daily to offset the combined hypotensive effects of carvedilol and furosemide, allowing maintenance of target carvedilol dose

5. [CASE 2 — QUESTION 5] P.L. is a 38-year-old woman with hypertension who is 22 weeks pregnant. She was previously on amlodipine 5 mg daily before conception, which was continued after confirmation of pregnancy. Her BP at today's visit is 162/104 mmHg — above her baseline of 138/86 mmHg. She has 1+ proteinuria on dipstick. She has no headache, visual changes, or right upper quadrant pain. Her obstetric team is evaluating her for superimposed preeclampsia and considering additional antihypertensive therapy. Which of the following most correctly identifies the appropriate antihypertensive additions and exclusions for P.L.'s specific clinical situation?

• A) Add lisinopril 10 mg daily — RAAS inhibitors are safe after the first trimester; the renal protective effects are particularly important in a patient developing proteinuria from superimposed preeclampsia
• B) Add spironolactone 25 mg daily — mineralocorticoid receptor blockade addresses the aldosterone-driven sodium retention underlying gestational hypertension and is safe in pregnancy at this dose
• C) Add hydrochlorothiazide 25 mg daily — thiazide diuretics are safe in pregnancy after the first trimester and reduce the volume expansion driving the BP elevation
• D) Add methyldopa 250 mg three times daily — methyldopa has the longest safety record of any antihypertensive in pregnancy and is appropriate as an add-on to amlodipine; the combination is commonly used in clinical practice for escalating gestational hypertension
• E) Add labetalol 100 mg twice daily as the primary add-on — it is one of three guideline-endorsed first-line agents in pregnancy hypertension; amlodipine (a DHP CCB) can be continued as it is also considered acceptable in pregnancy in many guidelines; the combination provides complementary alpha-1/beta-1 blockade (labetalol) plus L-type calcium channel blockade (amlodipine); ACEi, ARBs, and direct renin inhibitors remain absolutely contraindicated; spironolactone is avoided due to fetal anti-androgenic effects; thiazide diuretics are avoided due to volume contraction risk; methyldopa is also an acceptable alternative to labetalol if it is better tolerated

6. [CASE 2 — QUESTION 6] P.L. is started on labetalol 100 mg twice daily alongside her amlodipine 5 mg daily. At 28 weeks her BP is 148/96 mmHg — improved but above target. Labetalol is increased to 200 mg twice daily. At 32 weeks her BP is 158/100 mmHg — worsening despite adherence. She now has 2+ proteinuria and platelet count is 142,000/μL (mildly reduced). The obstetric team diagnoses severe preeclampsia and plans hospital admission. Her BP acutely spikes to 178/114 mmHg on the labor and delivery unit. Which of the following correctly identifies the pharmacological management of her acute severe hypertension in this setting?

• A) Oral nifedipine immediate-release 10 mg — the standard of care for acute severe hypertension in pregnancy; it achieves reliable BP reduction within 20–30 minutes through L-type calcium channel blockade
• B) IV magnesium sulfate as the first agent — magnesium is both an antihypertensive and a seizure prophylaxis agent in preeclampsia, making it the most efficient single intervention for this patient
• C) IV hydralazine 5–10 mg — the most commonly used IV antihypertensive in acute severe hypertension of pregnancy; its selective arteriolar dilation reduces BP without affecting uteroplacental flow
• D) IV labetalol 20 mg over 2 minutes, with repeat doses every 10 minutes if needed (doubling each time, up to 300 mg total); alternatively, oral nifedipine IR 10–20 mg can be used if IV access is not immediately available; IV hydralazine is a third option; the target is a BP reduction to 140–155/90–105 mmHg — not normalization — to avoid placental hypoperfusion; magnesium sulfate for seizure prophylaxis should also be initiated concurrently but it is not an antihypertensive agent
• E) IV esmolol infusion — its ultra-short half-life provides precise, titratable BP control that is superior to labetalol for acute severe hypertension in pregnancy

7. [CASE 2 — QUESTION 7] P.L. delivers at 34 weeks via emergency cesarean section. Mother and infant are stable. The infant requires NICU care for prematurity but has no specific drug-related complications. P.L.'s postpartum BP is 158/98 mmHg on day 2. She wishes to breastfeed. Her obstetric team plans to continue antihypertensive therapy postpartum. Which of the following most accurately identifies the appropriate antihypertensive strategy and the considerations specific to breastfeeding?

• A) Resume lisinopril 10 mg daily — ACEi are safe in breastfeeding because the protein binding of ACEi molecules prevents transfer into breast milk; they are the preferred antihypertensive post-delivery due to their renoprotective properties
• B) Continue labetalol and amlodipine with monitoring — both agents are considered compatible with breastfeeding by the American Academy of Pediatrics and major lactation databases; labetalol transfers into breast milk in small amounts but neonatal plasma levels are low and clinical effects in healthy infants are not reported at maternal antihypertensive doses; amlodipine transfers in small amounts but is generally considered low risk; the mother should be counseled to monitor the infant for excessive sedation or bradycardia; if BP remains uncontrolled, nifedipine ER is also considered compatible with breastfeeding
• C) Discontinue all antihypertensives — postpartum hypertension invariably resolves within 48 hours of delivery and pharmacological treatment beyond that point is unnecessary
• D) Switch to methyldopa — it is the only antihypertensive considered absolutely safe in breastfeeding; all other agents including labetalol and CCBs are contraindicated during lactation
• E) Switch to atenolol — atenolol is the preferred beta-blocker in breastfeeding because its hydrophilicity prevents transfer into breast milk; labetalol is contraindicated during breastfeeding due to its lipophilicity

8. [CASE 2 — QUESTION 8] P.L. is discharged on labetalol 200 mg twice daily and amlodipine 5 mg daily. Six weeks postpartum, her BP is 132/82 mmHg and she is feeling well. She asks whether she will need antihypertensives long-term. Her obstetrician explains that her BP may normalize as pregnancy-related hemodynamic changes resolve. At her 3-month postpartum visit, BP is 124/78 mmHg. The labetalol is tapered and discontinued; amlodipine is continued at 2.5 mg. At her 6-month postpartum visit, BP is 138/86 mmHg on amlodipine 2.5 mg. She asks about future pregnancy planning and whether her antihypertensive regimen would need to change if she becomes pregnant again. Which of the following most accurately advises her?

• A) If she becomes pregnant again, amlodipine should be continued as it is considered acceptable in pregnancy; if BP escalates, labetalol or methyldopa can be added as the primary add-on agents; ACEi, ARBs, and direct renin inhibitors must be avoided throughout all trimesters; she should be counseled that her history of superimposed preeclampsia significantly increases her risk of preeclampsia in future pregnancies — low-dose aspirin (81–162 mg daily) initiated between 12 and 16 weeks gestation has been shown to reduce preeclampsia recurrence risk in high-risk patients
• B) She should switch to lisinopril before her next pregnancy to optimize preconceptional renal protection, then discontinue it immediately upon a positive pregnancy test
• C) She should avoid pregnancy entirely — a history of severe preeclampsia is an absolute medical contraindication to future pregnancy
• D) No medication changes are needed for future pregnancy — all current antihypertensives are safe throughout pregnancy and no additional prophylactic measures are required
• E) She should switch to methyldopa as her primary antihypertensive between pregnancies so that no medication change is needed when she becomes pregnant again

9. [CASE 3 — QUESTION 9] R.V. is a 45-year-old woman with hypertension and recurrent episodic severe headaches, palpitations, diaphoresis, and pallor occurring two to three times per week, each lasting 15–30 minutes. Between episodes her BP is 148/92 mmHg; during an episode documented in the ED her BP reached 228/136 mmHg with heart rate 118 bpm. Her primary care physician suspects pheochromocytoma. Urine catecholamines and metanephrines are sent. While awaiting results, her physician considers empiric antihypertensive therapy for her ongoing hypertension. Which of the following most accurately identifies the pharmacological approach during the diagnostic workup phase — before surgical planning?

• A) Start metoprolol succinate 50 mg daily immediately — beta-1 selective blockade will control the episodic hypertension and tachycardia without the risk of unopposed alpha-1 vasoconstriction, since cardioselective agents spare beta-2 receptors
• B) Start propranolol 40 mg twice daily — non-selective beta-blockade will completely control both the adrenergic tachycardia and the vasoconstriction driven by catecholamines; it is the safest empiric agent while awaiting biochemical confirmation
• C) Avoid beta-blockers of any selectivity until pheochromocytoma is excluded or alpha-blockade is established; if antihypertensive treatment is needed during the workup period, use agents that do not block beta-2 receptors — a calcium channel blocker (amlodipine or nicardipine) is pharmacologically safe as it addresses the vasoconstrictive hypertension without the risk of removing beta-2-mediated vasodilation in the context of possible catecholamine excess; alpha-blockers (phenoxybenzamine or doxazosin) can also be used once the clinical suspicion is high
• D) Start spironolactone 25 mg daily — mineralocorticoid receptor blockade addresses the aldosterone excess that frequently accompanies pheochromocytoma and will control the episodic hypertension without adrenergic receptor interactions
• E) Start clonidine 0.1 mg twice daily — centrally acting alpha-2 agonism will reduce sympathetic outflow and control the episodic catecholamine surges; the clonidine suppression test can simultaneously confirm or exclude pheochromocytoma

10. [CASE 3 — QUESTION 10] Biochemical confirmation is obtained — 24-hour urine metanephrine 5.8 mg (normal less than 1.0 mg) and normetanephrine 12.4 mg (normal less than 1.7 mg). CT abdomen and pelvis identifies a 3.8 cm right adrenal mass. The endocrinologist confirms pheochromocytoma and plans laparoscopic adrenalectomy in 4 weeks after adequate pharmacological preparation. R.V. is started on phenoxybenzamine 10 mg twice daily, titrated to 20 mg twice daily over 10 days. She develops significant orthostatic hypotension (drop of 32 mmHg systolic on standing) with dizziness and palpitations. Her physician counsels her that this orthostatic hypotension is a therapeutic target rather than an adverse effect. Which of the following most accurately explains why orthostatic hypotension is considered a sign of adequate preoperative preparation and what the physiological basis for this interpretation is?

• A) Orthostatic hypotension indicates that phenoxybenzamine has blocked all peripheral alpha-1 receptors — complete receptor blockade is required before surgery can proceed safely
• B) Orthostatic hypotension is a sign of adequate preoperative preparation because it reflects successful alpha-1 blockade across the vascular bed; more importantly, it indicates that the chronic catecholamine-mediated vasoconstriction has been reversed, allowing compensatory volume expansion to occur; patients with pheochromocytoma are chronically volume-contracted (due to years of sympathetically-driven vasoconstriction reducing venous capacitance) — this volume contraction must be corrected before surgery because after tumor removal, the sudden loss of catecholamine drive causes profound hypotension in a volume-depleted patient; orthostatic hypotension emerging during alpha-blocker preparation therefore signals that the vascular tone is relaxing and the patient is appropriately expanding their intravascular volume with dietary sodium liberalization and hydration
• C) Orthostatic hypotension during phenoxybenzamine preparation indicates that the dose is too high and must be reduced before surgery to avoid excessive intraoperative hypotension
• D) Orthostatic hypotension indicates renal impairment from phenoxybenzamine's direct nephrotoxic effect on the juxtaglomerular apparatus; creatinine must be checked before proceeding
• E) Orthostatic hypotension during phenoxybenzamine preparation is a marker of adequate alpha-1 receptor blockade indicating successful peripheral vasodilation; it also signals the physiological reversal of chronic catecholamine-driven volume contraction, allowing intravascular volume to expand through dietary sodium liberalization and fluid intake; this volume expansion is critical because at the moment of tumor removal intraoperatively, the sudden loss of catecholamine drive causes abrupt vasodilation — a volume-replete patient will maintain hemodynamic stability while a volume-contracted patient will develop severe hypotension requiring vasopressors; phenoxybenzamine's orthostatic hypotension is therefore a therapeutic endpoint confirming adequate preparation

11. [CASE 3 — QUESTION 11] After 12 days of phenoxybenzamine 20 mg twice daily, R.V. develops persistent tachycardia with a resting heart rate of 108 bpm despite adequate alpha blockade and volume expansion. Her BP is well controlled at 118/72 mmHg. Her endocrinologist decides to add a beta-blocker. Which of the following most accurately identifies the appropriate beta-blocker choice and the essential prerequisite that has already been met before this addition?

• A) Start propranolol 80 mg three times daily immediately — high-dose non-selective beta-blockade is required for complete adrenergic control in pheochromocytoma; the dose must be maximized before surgery regardless of heart rate response
• B) Start atenolol 25 mg daily — its renal elimination and hydrophilicity make it safer than lipophilic beta-blockers in pheochromocytoma where hepatic blood flow may be reduced by catecholamine-mediated splanchnic vasoconstriction
• C) Beta-blockers remain contraindicated even after alpha-blockade is established — the risk of rebound tachycardia after tumor removal makes adding any beta-blocker perioperatively dangerous
• D) Start propranolol 10–20 mg three times daily or metoprolol 25–50 mg twice daily at a low dose and titrate to achieve heart rate below 80–90 bpm; the essential pharmacological prerequisite — alpha-blockade established first — has been met after 12 days of phenoxybenzamine; the beta-blocker is added only to control the tachycardia that emerged after alpha vasodilation, not to lower blood pressure; the dose required is often modest
• E) Start carvedilol 6.25 mg twice daily — its combined alpha-1 and beta-blockade provides additional alpha blockade complementary to phenoxybenzamine, and the combined adrenergic blockade is superior to phenoxybenzamine alone for intraoperative catecholamine surge control

12. [CASE 3 — QUESTION 12] R.V. undergoes successful laparoscopic right adrenalectomy. Intraoperatively, BP surges to 248/138 mmHg during tumor manipulation, managed with IV phentolamine and nitroprusside. After tumor removal, BP falls to 88/52 mmHg, managed with IV norepinephrine infusion. She is admitted to ICU postoperatively. By day 2, she is hemodynamically stable off vasopressors. Her BP on day 3 is 122/78 mmHg. She asks whether she still needs blood pressure medications. Which of the following most accurately addresses her postoperative antihypertensive management?

• A) Restart phenoxybenzamine immediately — residual catecholamine excess from adrenal medullary hyperplasia persists for weeks after adrenalectomy and requires continued alpha-blockade
• B) Discontinue all antihypertensives and monitor BP — the majority of patients with unilateral pheochromocytoma become normotensive after successful surgical resection; phenoxybenzamine and the perioperative beta-blocker should be discontinued; BP should be monitored closely over the following weeks; if hypertension persists beyond 1–3 months postoperatively, evaluation for residual disease, metastatic pheochromocytoma, or coexisting essential hypertension should be performed; biochemical testing (plasma or urine metanephrines) should be repeated at 2–6 weeks postoperatively to confirm cure
• C) Restart labetalol and monitor — hypertension invariably returns within 72 hours of pheochromocytoma resection due to rebound catecholamine receptor upregulation from the prior catecholamine excess
• D) Continue all perioperative medications indefinitely — surgical resection does not cure pheochromocytoma; the biochemical abnormalities persist regardless of tumor removal
• E) Start an ACEi — RAAS activation from the prior catecholamine-mediated renin release persists for months after tumor removal and requires RAAS blockade as definitive antihypertensive therapy

13. [CASE 4 — QUESTION 13] T.W. is a 76-year-old man with severe treatment-resistant hypertension (BP 198/104 mmHg despite confirmed adherence to lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily). Secondary causes have been excluded. PRA is 0.2 ng/mL/hr (suppressed). Potassium is 3.9 mEq/L. eGFR is 44 mL/min/1.73m2. He has no heart failure and no history of MI. His cardiologist adds spironolactone 25 mg daily as a fourth agent. After 8 weeks, BP is 154/90 mmHg and potassium is 4.8 mEq/L. The cardiologist considers whether minoxidil should be initiated as a fifth agent. Which of the following most accurately identifies the pharmacological prerequisite assessment before starting minoxidil in T.W.?

• A) Before initiating minoxidil, the current diuretic (chlorthalidone) must be switched to a loop diuretic — at eGFR 44, chlorthalidone has substantially reduced efficacy for the degree of sodium retention minoxidil causes; a loop diuretic (torsemide preferred for predictable bioavailability) is required; a beta-blocker must also be present to prevent reflex tachycardia — if the regimen does not already include one, bisoprolol should be added before minoxidil; the current regimen lacks a beta-blocker, which is a mandatory co-prescription; minoxidil should not be started until both the loop diuretic and beta-blocker are in place
• B) Before initiating minoxidil, spironolactone must be discontinued — minoxidil causes hyperkalemia through KATP channel opening in renal tubular cells, and combining it with spironolactone creates dangerous additive hyperkalemia
• C) No prerequisite changes are needed — T.W. already has adequate diuresis from chlorthalidone 25 mg at eGFR 44 and spironolactone 25 mg combined; minoxidil can be started at 5 mg daily with his current regimen
• D) The only prerequisite is potassium monitoring — potassium must be below 4.5 mEq/L before minoxidil initiation because KATP channel activation in renal cells causes potassium retention; spironolactone must be discontinued to lower potassium before proceeding
• E) Minoxidil is contraindicated in patients over 75 with eGFR below 50 — the combination of age-related pharmacokinetic changes and renal impairment causes unpredictable plasma accumulation of the active sulfate metabolite

14. [CASE 4 — QUESTION 14] Chlorthalidone is switched to torsemide 10 mg daily and bisoprolol 5 mg daily is added. Two weeks later, potassium is 4.1 mEq/L, heart rate is 62 bpm, and BP is 152/88 mmHg. The cardiologist initiates minoxidil 2.5 mg daily. At 4 weeks, BP is 136/84 mmHg and the patient has gained 3 kg. He has mild bilateral ankle edema but no orthopnea. Which of the following most accurately identifies the appropriate next step?

• A) Discontinue minoxidil — the 3 kg weight gain and edema indicate that the drug is causing heart failure decompensation; loop diuretics cannot manage minoxidil-induced fluid retention
• B) Reduce minoxidil to 1.25 mg — the weight gain indicates the dose is above the threshold causing fluid retention; lower doses do not cause sodium retention
• C) Increase torsemide from 10 mg to 20 mg daily — the 3 kg weight gain and ankle edema represent inadequate diuretic response to minoxidil's sodium retention; escalating the loop diuretic dose is the correct first response to minoxidil-associated fluid retention; if edema resolves and weight returns to baseline, minoxidil can be continued; if additional BP control is needed after volume optimization, minoxidil can be uptitrated to 5 mg
• D) Add spironolactone 25 mg to counteract the aldosterone-mediated sodium retention from minoxidil's RAAS activation — potassium is now 4.1 mEq/L and the MRA can safely be resumed to provide both diuresis and potassium protection
• E) Switch torsemide to furosemide 80 mg IV daily for 3 days to rapidly deplete the retained sodium before continuing oral therapy

15. [CASE 4 — QUESTION 15] Torsemide is increased to 20 mg daily. At 4 weeks, weight has returned to baseline and ankle edema has resolved. BP is 132/82 mmHg on the full regimen (lisinopril 40 mg, amlodipine 10 mg, torsemide 20 mg, spironolactone — now restarted at 12.5 mg given normalized potassium, bisoprolol 5 mg, and minoxidil 2.5 mg daily). He asks about the hair growth he has developed on his arms, shoulders, and face. He finds it cosmetically distressing. Which of the following most accurately explains the mechanism of his hair growth and the management options?

• A) The hair growth is caused by bisoprolol's stimulation of beta-3 receptors in hair follicles — switching to a non-vasodilatory beta-blocker will reverse the hypertrichosis
• B) The hair growth is a class effect of loop diuretics caused by torsemide's stimulation of KATP channels in hair follicle dermal papilla cells — switching to furosemide will eliminate this effect
• C) The hair growth is caused by spironolactone's anti-androgenic effects paradoxically stimulating female-pattern hair growth through progesterone receptor activation — discontinuing spironolactone will resolve the hypertrichosis
• D) The hair growth is an expected and near-universal adverse effect of systemic minoxidil — hypertrichosis occurs in virtually all patients on oral minoxidil due to the KATP channel-mediated prolongation of the hair follicle anagen (growth) phase in skin; it is the same mechanism exploited therapeutically in topical minoxidil preparations for androgenetic alopecia; management options include: (1) accepting the cosmetic change as the trade-off for BP control; (2) cosmetic hair removal (laser, waxing); (3) if intolerable, reducing the minoxidil dose (which may worsen BP control) or discontinuing minoxidil (which will require alternative fifth-line antihypertensive options, of which few exist); topical eflornithine can reduce facial hair growth rate as a cosmetic adjunct
• E) The hair growth is an expected and near-universal adverse effect of systemic minoxidil — hypertrichosis results from KATP channel-mediated prolongation of the hair follicle anagen phase; it is the same mechanism exploited in topical minoxidil for androgenetic alopecia; it affects face, arms, back, and legs; management options include cosmetic measures (laser hair removal, waxing, bleaching), topical eflornithine for facial hypertrichosis reduction, or dose reduction as a last resort; discontinuation should be reserved for cases where hypertrichosis is truly intolerable after exhausting cosmetic options, given the difficulty of achieving equivalent BP control by other means in this truly resistant patient

16. [CASE 4 — QUESTION 16] T.W. accepts the hypertrichosis and continues his regimen. At 6-month review, BP is 128/80 mmHg — at target. His echocardiogram shows new mild-to-moderate pericardial effusion (estimated 200 mL). He is hemodynamically stable with no signs of tamponade. He has no fever, no pleuritic chest pain, and ANA is negative. Which of the following most accurately identifies the diagnosis, mechanism, and management?

• A) This is immune-mediated pericarditis caused by minoxidil; the drug must be immediately discontinued and oral prednisone 1 mg/kg daily started for 4 weeks
• B) This is malignant pericardial effusion from an occult malignancy triggered by minoxidil's KATP channel opening in pericardial mesothelial cells; CT chest/abdomen/pelvis for cancer staging is the urgent next step
• C) This is minoxidil-associated pericardial effusion — a recognized adverse effect occurring in approximately 3% of patients; the mechanism is transudative fluid accumulation driven by minoxidil's sodium retention and secondary RAAS activation; the effusion is not inflammatory or exudative; management is intensification of loop diuretic therapy (increase torsemide from 20 mg to 40 mg daily) and close monitoring; if the effusion progresses or hemodynamic compromise develops, minoxidil discontinuation and pericardiocentesis may be required
• D) This is minoxidil-associated pericardial effusion — a recognized transudative adverse effect from minoxidil's sodium retention and secondary RAAS activation; the effusion is hemodynamically stable without tamponade; the appropriate first step is intensification of diuretic therapy (increase torsemide); echocardiographic follow-up at 4–6 weeks to confirm response; if the effusion fails to respond to maximized diuretic therapy or progresses toward tamponade physiology, minoxidil should be discontinued; pericardiocentesis is reserved for tamponade or hemodynamic compromise; ANA negativity and absence of systemic inflammatory features argue against inflammatory or immune-mediated pericarditis
• E) This is an incidental finding unrelated to minoxidil; pericardial effusions of this size are common in elderly men with hypertension and require no treatment or medication adjustment

17. [CASE 5 — QUESTION 17] U.K. is a 59-year-old man with hypertension, type 2 diabetes, and bilateral carotid artery stenosis (right 70%, left 55% on duplex ultrasound). He presents with BP 172/96 mmHg on lisinopril 20 mg and amlodipine 5 mg daily. His cardiologist considers adding a beta-blocker for additional BP control and asks whether the carotid stenosis changes the drug selection. Which of the following most accurately evaluates the use of beta-blockers in a patient with significant carotid artery stenosis?

• A) Beta-blockers are absolutely contraindicated in bilateral carotid stenosis because the heart rate reduction they cause reduces cerebral blood flow below the autoregulatory threshold in stenotic carotid territory
• B) Beta-blockers can be used with appropriate caution in patients with carotid stenosis — the primary pharmacological concern is not the bradycardia itself but the potential for hypotension in patients with fixed carotid stenosis; cerebral perfusion in stenotic territory depends critically on blood pressure, particularly in those with severe bilateral disease or impaired autoregulation; a cardioselective agent (bisoprolol or metoprolol succinate) at a low initial dose is appropriate; the patient should be monitored for symptoms of cerebral hypoperfusion (dizziness, visual changes, transient neurological symptoms); the goal is careful BP lowering that reduces cardiovascular risk without dropping BP below the cerebral autoregulatory range
• C) The carotid stenosis makes beta-blockers unnecessary — carotid stenosis itself reduces the sympathetic drive to hypertension through baroreceptor impairment; antihypertensive therapy is less effective in patients with carotid atherosclerosis
• D) A non-selective beta-blocker (propranolol) is preferred in carotid stenosis over cardioselective agents because propranolol's cerebral penetration allows direct modulation of cerebrovascular tone through central beta-receptor effects
• E) Beta-blockers are the preferred antihypertensive in carotid stenosis because their negative chronotropy reduces the mechanical shear stress on the carotid plaque during cardiac systole, stabilizing the plaque and reducing embolization risk

18. [CASE 5 — QUESTION 18] Bisoprolol 2.5 mg daily is added and titrated to 5 mg daily over 4 weeks. U.K.'s BP is now 148/88 mmHg and heart rate is 58 bpm. He develops new mild fatigue and notes his exercise tolerance has decreased modestly. His blood glucose control has also worsened slightly (HbA1c 7.8% from 7.4%). His cardiologist asks whether these adverse effects should prompt a dose reduction or agent change. Which of the following most accurately guides the clinical decision regarding U.K.'s beta-blocker adverse effects?

• A) The fatigue and reduced exercise tolerance are real beta-blocker adverse effects — mediated through reduced cardiac output reserve during exertion — and the glycemic worsening reflects beta-blocker impairment of catecholamine-driven insulin secretion and glucose uptake; the clinical decision depends on the indication: if bisoprolol is being used solely for hypertension without a compelling indication (no post-MI, no HFrEF, no AF rate control requirement), these quality-of-life and metabolic impacts may justify reassessing whether a different drug class would achieve equivalent BP control with fewer adverse effects; if bisoprolol is providing essential cardiovascular protection, these effects must be tolerated or managed by optimizing diabetes therapy
• B) The fatigue and exercise intolerance indicate that bisoprolol is causing acute HFrEF — a previously unrecognized systolic dysfunction has been unmasked by the negative inotropy; an urgent echocardiogram is required and bisoprolol must be stopped immediately
• C) The glycemic worsening proves that beta-blockers are absolutely contraindicated in type 2 diabetes; bisoprolol must be stopped and replaced with an alpha-1 blocker which does not interact with glucose metabolism
• D) Both adverse effects will resolve over 4–6 weeks as baroreceptor and metabolic adaptation occurs; no medication adjustment is needed and the patient should be reassured
• E) The fatigue indicates bisoprolol has achieved complete beta-1 receptor saturation; reducing the dose to 2.5 mg will maintain antihypertensive efficacy while completely eliminating the fatigue without any loss of cardiovascular benefit

19. [CASE 5 — QUESTION 19] U.K.'s cardiologist decides to discontinue bisoprolol given the adverse effects and the absence of a compelling indication. He titrates it down over 2 weeks (5 mg → 2.5 mg → stop). Lisinopril is increased to 40 mg daily. Two weeks after bisoprolol is stopped, U.K. presents with BP 186/108 mmHg and heart rate 102 bpm. He reports that his energy has returned and exercise tolerance is improved. He is anxious about his rising blood pressure. Which of the following most accurately explains the BP and heart rate changes seen 2 weeks after bisoprolol discontinuation, despite the lisinopril increase?

• A) The BP rise represents inadequate antihypertensive efficacy of lisinopril at 40 mg; the lisinopril dose should be doubled to 80 mg
• B) The BP and heart rate rise indicate that U.K. has developed new essential hypertension exacerbation unrelated to the bisoprolol discontinuation; a full secondary hypertension workup should be repeated
• C) The BP and heart rate rise represent pseudohypertension from aortic stiffness — a normal phenomenon in 59-year-old men with carotid atherosclerosis that does not require treatment
• D) The BP and heart rate rise represent beta-blocker withdrawal — during chronic bisoprolol therapy, beta-1 receptors upregulate (increase in number and sensitivity) in response to chronic blockade; when bisoprolol is discontinued, even after a 2-week taper, these upregulated receptors respond to normal catecholamine levels with exaggerated chronotropic and vasopressor responses; the increased heart rate (102 bpm) and BP (186/108 mmHg) are consistent with adrenergic rebound; management is to monitor closely (symptoms typically resolve over 1–2 weeks as receptor density normalizes) and add amlodipine 5 mg or increase lisinopril if BP remains elevated after the rebound phase; urgent beta-blocker restart is not required if the patient is asymptomatic and has no ischemic symptoms, but angina, chest pain, or ECG changes would warrant immediate beta-blocker reinstatement
• E) The BP and heart rate rise indicate that U.K. was actually dependent on bisoprolol for pheochromocytoma-driven hypertension suppression; catecholamine workup should be urgently repeated

20. [CASE 5 — QUESTION 20] Over the next 3 weeks, U.K.'s BP stabilizes at 142/88 mmHg on lisinopril 40 mg and amlodipine 10 mg (titrated up). His heart rate normalizes to 72 bpm as beta-adrenoceptor density returns to normal. His cardiologist now wants to ensure optimal secondary stroke prevention given the bilateral carotid stenosis. A neurologist colleague suggests adding low-dose aspirin and a statin, but also recommends avoiding any antihypertensive that might further lower diastolic BP given the right-sided 70% stenosis. Which of the following most accurately reflects the evidence-based approach to BP targets in patients with significant carotid stenosis and the role of diastolic BP in this context?

• A) BP should not be lowered below 160/90 mmHg in patients with bilateral carotid stenosis — aggressive BP reduction always causes watershed infarction in territory distal to the stenosis
• B) The target BP in carotid stenosis should be determined by the degree of stenosis — for stenosis below 50%, standard targets apply; for stenosis 50–70%, target is 140–150/90–100 mmHg; for stenosis above 70%, target is above 150/100 mmHg to maintain perfusion pressure
• C) Current evidence supports a target systolic BP below 140 mmHg in most patients with carotid stenosis, including those with significant bilateral disease, as long as titration is gradual and the patient is monitored for cerebral hypoperfusion symptoms; the J-curve concern (harm from excessive diastolic lowering) is most clinically relevant in coronary artery disease where diastolic coronary perfusion is critical; for cerebrovascular disease with carotid stenosis, the primary concern is systolic pressure driving stroke risk, and gradual reduction to standard targets is appropriate; diastolic BP of 80–85 mmHg is generally safe in this population; avoiding antihypertensives based on diastolic concerns alone — without evidence of symptoms or hemodynamic compromise — is not guideline-supported
• D) Antihypertensive therapy should be discontinued entirely in patients with bilateral carotid stenosis greater than 50% — blood pressure elevation in these patients represents a homeostatic compensatory mechanism to maintain cerebral perfusion and should not be pharmacologically opposed
• E) The standard BP target (below 130/80 mmHg per 2017 ACC/AHA guidelines) should be achieved as rapidly as possible in carotid stenosis to minimize stroke risk; intensive acute BP lowering of 30–40 mmHg within 24 hours is the recommended approach

21. [CASE 6 — QUESTION 21] V.M. is a 52-year-old woman with hypertension who presents with her husband, who reports she has been increasingly forgetful and fatigued over the past 3 months. She started clonidine 0.2 mg twice daily 4 months ago, added by a previous provider for refractory hypertension. Her current regimen is losartan 100 mg, amlodipine 10 mg, and clonidine 0.2 mg twice daily. BP is 132/78 mmHg — well controlled. She scores 24/30 on the MMSE (mild cognitive impairment range). Her physician suspects clonidine is contributing to her cognitive symptoms. Which of the following most accurately identifies the pharmacological basis for this concern and the appropriate management strategy?

• A) Clonidine causes cognitive impairment through central histamine H1 receptor blockade, identical to first-generation antihistamines; switching to a second-generation centrally acting agent will eliminate the cognitive effects
• B) Clonidine's cognitive effects are mediated through alpha-2 receptor stimulation in the prefrontal cortex, which impairs working memory and executive function; paradoxically, low-dose clonidine is used therapeutically for ADHD — the dose used here (0.2 mg twice daily) is above the therapeutic cognitive window and must be reduced
• C) Clonidine does not cause cognitive impairment; the MMSE decline is consistent with early dementia unrelated to the medication; neurological workup should be initiated
• D) Clonidine's central alpha-2 agonism produces sedation that impairs arousal and attentiveness, contributing to perceived cognitive decline; additionally, the elderly and middle-aged patients may be disproportionately sensitive to these CNS effects; management is to taper clonidine slowly (never abruptly) and switch to a non-CNS-penetrating antihypertensive; if a centrally acting agent is needed, moxonidine (preferentially acting on imidazoline I1 receptors with less alpha-2A sedation) could be considered as a better-tolerated alternative; the taper must be gradual to avoid withdrawal hypertensive crisis
• E) Clonidine's central alpha-2A receptor stimulation in the locus coeruleus reduces noradrenergic output to the cortex, producing sedation and impairing arousal, attention, and cognitive processing — effects that can manifest as apparent cognitive decline, particularly in middle-aged and older patients who are more sensitive to CNS depressants; management requires slow tapering (clonidine must never be stopped abruptly — withdrawal hypertensive crisis risk); as BP is already well controlled, consider reducing the clonidine dose stepwise over weeks while monitoring BP; if a fourth antihypertensive is needed after clonidine taper, moxonidine (imidazoline I1 selective, less alpha-2A sedation) or a low-dose thiazide are better-tolerated alternatives; neurological evaluation should also be arranged to exclude concurrent primary cognitive disease

22. [CASE 6 — QUESTION 22] Clonidine is tapered and discontinued over 6 weeks with close BP monitoring. At the end of the taper, BP is 144/88 mmHg — slightly above target without the clonidine. V.M.'s cognitive symptoms have significantly improved; her repeat MMSE score is 28/30. Neurological evaluation finds no evidence of primary dementia. Her physician wants to add a fourth antihypertensive to replace the clonidine's BP-lowering effect without CNS adverse effects. Which of the following most accurately evaluates the options for a fourth antihypertensive in V.M.?

• A) Add clonidine at a reduced dose of 0.1 mg twice daily — the lower dose will provide BP control without cognitive adverse effects; the cognitive impairment was dose-related and will not recur at this dose
• B) Add chlorthalidone 12.5 mg daily — a thiazide-type diuretic is pharmacologically appropriate as a fourth antihypertensive; it provides a volume-based BP reduction through NCC inhibition that is mechanistically distinct from and complementary to the existing losartan (RAAS inhibition) and amlodipine (arteriolar vasodilation); it has no CNS adverse effects; PRA and potassium should be checked before initiation — if PRA is suppressed (low renin, volume-dependent physiology), the thiazide will be particularly effective and may prompt consideration of spironolactone as an alternative fourth agent given the PATHWAY-2 evidence
• C) Add moxonidine 0.2 mg daily — its imidazoline I1 selectivity eliminates all centrally mediated adverse effects; it is safe in all patients with a history of clonidine-related cognitive impairment
• D) Add doxazosin 1 mg at bedtime — alpha-1 blockade provides the most effective fourth-line antihypertensive option based on PATHWAY-2 evidence; V.M.'s prior difficulty with clonidine makes centrally acting agents contraindicated
• E) Add bisoprolol 5 mg daily — beta-blockers have no CNS adverse effects and provide the most cardiovascular protection as a fourth agent in resistant hypertension based on PATHWAY-2

23. [CASE 6 — QUESTION 23] Chlorthalidone 12.5 mg daily is added. At 8 weeks, BP is 128/78 mmHg — at target. PRA was measured before initiation: it was 0.2 ng/mL/hr (suppressed). Potassium is 3.8 mEq/L. The physician considers whether, given the suppressed PRA suggesting volume-dependent physiology, spironolactone would have been a better choice than chlorthalidone. Which of the following most accurately addresses whether chlorthalidone or spironolactone would be the superior fourth agent in this specific patient, and whether switching is warranted?

• A) Spironolactone is superior in all patients with suppressed PRA and should replace chlorthalidone immediately — the PATHWAY-2 evidence mandates spironolactone as first choice in low-renin hypertension and any other choice represents suboptimal care
• B) Chlorthalidone and spironolactone are equally effective in low-renin hypertension; the choice between them is arbitrary and switching provides no clinical benefit
• C) Spironolactone would have been the pharmacologically optimal fourth agent in this patient given the suppressed PRA — PATHWAY-2 demonstrated that spironolactone was the most effective fourth-line agent in resistant hypertension, with the strongest benefit in low-renin patients; however, since BP is now at target on chlorthalidone, switching is not clinically warranted; if BP were not at target, transitioning to spironolactone (or adding it as a fifth agent) would be appropriate; if chlorthalidone causes adverse effects (hypokalemia, hyperuricemia, metabolic effects), switching to spironolactone at that point would be clinically logical
• D) Switching to spironolactone is necessary because chlorthalidone's hyperuricemia risk in a 52-year-old woman significantly outweighs any antihypertensive benefit; spironolactone's uricosuric properties make it superior in this demographic
• E) Spironolactone should be added as a fifth agent to augment chlorthalidone — the combination of thiazide plus MRA is contraindicated only in patients with CKD; in patients with normal renal function it is always more effective than either agent alone

24. [CASE 6 — QUESTION 24] V.M. has been on losartan 100 mg, amlodipine 10 mg, and chlorthalidone 12.5 mg for 12 months with excellent BP control. She now presents to her physician asking about a dietary supplement she has read about — "hibiscus tea" — that she has seen advertised as having antihypertensive effects comparable to some medications. She is taking three antihypertensives and wonders if she could reduce her medication if she adds hibiscus tea. Her physician provides evidence-based counseling. Which of the following most accurately reflects the pharmacological and clinical evidence relevant to this discussion?

• A) Hibiscus tea (Hibiscus sabdariffa) has modest antihypertensive properties in randomized controlled trials — mechanisms proposed include ACE inhibition, diuretic effects, and alpha-adrenoceptor blockade; the estimated BP reduction is modest (4–7 mmHg systolic in some studies); it is safe as a dietary adjunct but does not replace pharmacological therapy; it may add modest additional BP reduction as a complementary measure but should not be used as a justification for reducing or discontinuing proven antihypertensive agents; additionally, there are theoretical interaction concerns with her existing regimen — hibiscus has ACE-inhibiting properties that could complement losartan but also compounds the risk of excessive antihypertensive effect; patients should inform their physicians before using it, and BP should be monitored after any dietary change
• B) Hibiscus tea has no pharmacological basis for antihypertensive activity and all published trials are of low quality; she should be firmly discouraged from any dietary supplements
• C) Hibiscus tea contains hibiscin, which is a potent AT1 receptor antagonist equivalent to losartan 50 mg; adding it to her current regimen could produce dangerous dual RAAS blockade
• D) Hibiscus tea can replace chlorthalidone in patients whose hypertension responds to its diuretic mechanism — since her hypertension appears volume-dependent (suppressed PRA), hibiscus could provide equivalent diuresis without the metabolic effects of chlorthalidone
• E) Hibiscus tea interacts with amlodipine through CYP3A4 inhibition, raising plasma amlodipine levels by 40–60%; it must be avoided in any patient taking a DHP CCB

25. [CASE 7 — QUESTION 25] W.P. is a 68-year-old man with hypertension, stable angina (Canadian Cardiovascular Society Class II), and no history of MI or heart failure. BP is 158/92 mmHg on losartan 100 mg daily. His cardiologist wants to add a second agent that will simultaneously address his residual hypertension and his anginal symptoms. Which of the following most accurately identifies the pharmacologically optimal second agent and explains the dual mechanism?

• A) Add spironolactone 25 mg daily — MR blockade reduces both the preload excess driving his coronary demand and the aldosterone-driven vascular inflammation worsening coronary endothelial function
• B) Add hydrochlorothiazide 25 mg daily — volume reduction lowers preload and reduces cardiac wall stress, decreasing myocardial oxygen demand and improving the anginal threshold
• C) Add amlodipine 10 mg daily — the DHP CCB dilates coronary arteries (increasing myocardial oxygen supply) and reduces peripheral arteriolar resistance (decreasing afterload and myocardial wall stress); this simultaneously lowers blood pressure and improves anginal threshold; this combination is guideline-supported for stable angina and is the cornerstone of the CCB + RAAS inhibitor strategy with ACCOMPLISH evidence
• D) Add a long-acting beta-blocker (bisoprolol 5 mg daily or metoprolol succinate 50 mg daily) — beta-1 blockade reduces heart rate (extending diastole for coronary perfusion) and myocardial contractility (reducing oxygen demand), directly addressing the supply-demand mismatch causing angina; simultaneously, the reduced cardiac output and renin suppression lower blood pressure; the combination of an ARB (losartan, already present) and a beta-blocker addresses both systemic resistance and cardiac oxygen demand through complementary mechanisms; this dual antianginal and antihypertensive approach is guideline-recommended for stable angina
• E) Add clonidine 0.1 mg twice daily — central sympatholysis reduces the adrenergic drive to both heart rate and vascular tone, providing simultaneous antianginal and antihypertensive effects; it is particularly appropriate in CCS Class II angina where exercise-induced sympathetic activation is the primary trigger

26. [CASE 7 — QUESTION 26] Bisoprolol 5 mg daily is added. At 8 weeks, BP is 138/84 mmHg and anginal episodes have decreased from three per week to one per week. Heart rate is 56 bpm. W.P. develops worsening of pre-existing Raynaud phenomenon — his fingers are turning white and blue with mild cold exposure. He is distressed and asks whether the bisoprolol is responsible. Which of the following most accurately identifies whether bisoprolol caused the Raynaud worsening, and what should be done?

• A) Bisoprolol cannot cause Raynaud worsening — its high beta-1 selectivity means it has no effect on peripheral beta-2 receptors in digital vessels; a different cause of Raynaud exacerbation should be sought
• B) Bisoprolol has caused Raynaud worsening through its residual beta-2 blockade in peripheral digital vessels, removing the vasodilatory beta-2 counterbalance to alpha-1-mediated vasoconstriction; the appropriate management depends on the indication: since bisoprolol has a compelling dual indication here (angina + hypertension), the options are — (1) continue bisoprolol and add a DHP CCB (amlodipine or nifedipine ER) for Raynaud treatment, since DHP CCBs are the pharmacological treatment of choice for Raynaud phenomenon; (2) if Raynaud is intolerable, switch the antianginal component to amlodipine (which treats both angina through coronary vasodilation and Raynaud through digital vasodilation) in combination with losartan; in either case, the heart rate of 56 bpm suggests maximal beta-blockade is already present
• C) Bisoprolol is causing Raynaud worsening; the only management is permanent beta-blocker discontinuation and switching to a centrally acting agent (clonidine) which has no peripheral vascular effects
• D) The Raynaud worsening is caused by losartan — ARBs promote URAT1-mediated urate retention in digital vessels, triggering Raynaud attacks through urate crystal deposition in capillary beds; switching to a different ARB will resolve the digital vasospasm
• E) Bisoprolol has caused Raynaud worsening through residual beta-2 receptor blockade in digital vascular smooth muscle, tipping the vascular tone balance toward alpha-1-mediated vasoconstriction; the most pharmacologically elegant management is to switch bisoprolol to amlodipine — amlodipine (a DHP CCB) simultaneously addresses the stable angina (coronary vasodilation, afterload reduction), the hypertension (peripheral arteriolar dilation), and the Raynaud phenomenon (digital vasodilation through L-type calcium channel blockade in digital vessels); combined with losartan, the amlodipine + ARB regimen achieves the same dual angina/hypertension goals as bisoprolol + ARB while eliminating the beta-2 blockade responsible for Raynaud worsening; the CAMELOT trial supports amlodipine's benefit in stable CAD

27. [CASE 7 — QUESTION 27] Bisoprolol is tapered over 2 weeks and amlodipine 5 mg daily is added. At 6 weeks, W.P.'s Raynaud symptoms have resolved, anginal episodes remain at one per week, and BP is 142/86 mmHg — slightly above target. Amlodipine is uptitrated to 10 mg daily. At 12 weeks, BP is 132/82 mmHg, angina is occurring less than once every 2 weeks, and Raynaud symptoms have not returned. His physician considers whether losartan and amlodipine together provide the evidence-based cardiovascular protection of the specific RAAS inhibitor + CCB combination that has been studied in high-risk patients. Which of the following most accurately identifies the pharmacological evidence for this specific combination?

• A) The ACCOMPLISH trial compared benazepril (ACEi) + amlodipine versus benazepril + hydrochlorothiazide in high-cardiovascular-risk hypertensive patients — the ACEi + CCB combination reduced the primary composite endpoint of cardiovascular events by approximately 20% compared to ACEi + thiazide; while ACCOMPLISH used an ACEi (not an ARB), the pharmacological principle — that RAAS inhibition plus CCB provides superior cardiovascular protection to RAAS inhibition plus thiazide in high-risk patients — is broadly accepted; the combination of losartan (ARB) + amlodipine in W.P. provides mechanistically equivalent RAAS inhibition + CCB combination therapy that is guideline-supported; the ACCOMPLISH evidence should be considered broadly applicable to the ARB + CCB combination in the absence of a specific ARB + amlodipine outcome trial
• B) The ACCOMPLISH trial specifically tested losartan + amlodipine versus losartan + chlorthalidone; W.P.'s current regimen is therefore directly supported by ACCOMPLISH
• C) The CCB + RAAS inhibitor combination has no cardiovascular outcome trial evidence beyond blood pressure lowering; the combination is used only for its additive antihypertensive mechanism
• D) The ACCOMPLISH trial showed ACEi + thiazide was superior to ACEi + CCB; the CCB combination should be switched back to a thiazide for better cardiovascular protection
• E) The ACCOMPLISH combination benefit was demonstrated only in Black patients; in non-Black patients the CCB + RAAS inhibitor combination has no evidence advantage over other combinations

28. [CASE 7 — QUESTION 28] W.P. continues on losartan 100 mg and amlodipine 10 mg daily. At his annual review (18 months after starting this regimen), BP is 134/84 mmHg, anginal episodes are rare (less than once per month), and Raynaud phenomenon has not recurred. He has developed bilateral ankle edema (2+) that began 3 months ago. BNP is 32 pg/mL (normal). There is no evidence of heart failure. He is otherwise well. His physician identifies the cause and considers the management options. Which of the following most accurately identifies the mechanism of the edema and the best pharmacological management strategy in the context of W.P.'s specific therapeutic goals?

• A) The edema is caused by losartan-induced sodium retention; switching to an ACEi will correct the edema mechanism while maintaining RAAS inhibition
• B) The edema is caused by amlodipine-induced preferential arteriolar dilation without matched venodilation, raising capillary hydrostatic pressure in dependent tissues; the management options must preserve both his antianginal and antihypertensive goals — reducing amlodipine from 10 mg to 5 mg (dose-dependent edema) may reduce but not eliminate the edema while sacrificing some BP and anginal control; switching to felodipine (higher vascular selectivity, less peripheral edema at equivalent antihypertensive doses) maintains the DHP CCB class benefit; alternatively, ensuring losartan remains at maximum dose (100 mg — already present) preserves its venodilatory counteraction of CCB edema; a small dose of a thiazide (chlorthalidone 12.5 mg) could also be considered to counteract the sodium retention component, with monitoring for potassium
• C) The edema is caused by amlodipine-induced preferential arteriolar dilation raising capillary hydrostatic pressure; the most pharmacologically elegant management is to switch from amlodipine 10 mg to felodipine 5 mg — felodipine has higher vascular selectivity and produces less peripheral edema at equivalent antihypertensive doses; it maintains the DHP CCB class benefit for both angina and hypertension while reducing the hemodynamic edema mechanism; losartan should be maintained at maximum dose as its venodilatory effect partially counteracts CCB-mediated capillary hydrostatic pressure imbalance; BP and anginal control should be reassessed at 6 weeks after the switch
• D) The edema is caused by amlodipine-associated lymphatic obstruction; the only effective management is complete discontinuation of the CCB and replacement with a non-CCB antihypertensive
• E) The edema is caused by losartan-induced reduction in aldosterone, impairing sodium balance and causing extravascular fluid accumulation through a non-osmotic mechanism; adding fludrocortisone 0.05 mg daily will correct the sodium balance and resolve the edema